Free CME: Alzheimer’s Education
Thanks to a grant from Eisai Inc., the Rockpointe Corporation is offering CME approved dementia care education free this spring.
These sessions on recent advances in diagnosis and treatment are being offered as live virtual events. This training is a CME/AAFP, ABIM, MOC Activity. Participants will need to register individually in order to complete the post-test and evaluation to receive credit.
- Welcome and Introduction
- Detecting Mild Cognitive Impairment and Decline Early in the Course of Disease
- Current and Emerging Therapies for AD
- Q & A Session and Activity Roundup
With the number of Alzheimer’s disease (AD) specialists limited in many parts of the country, many primary care physicians (PCPs) must provide care, often beyond their level of training or expertise, for patients with AD or early signs of AD. Too often early signs and symptoms of AD are missed or not given appropriate priority, and thus specialty referrals occur later in the course of disease. Furthermore, the difficulty in diagnosing AD and the lack of any disease modifying therapy (DMT) for AD has fostered clinical inertia among many physicians. However, the approval of the first blood test for AD in November 2020 and the first DMT medication, aducanumab, in June 2021, should begin to provide the he medicines, equipment, and techniques available to a medical practitioner that has been missing from AD management since it was first characterized.
Given that 85% of initial AD diagnoses are made by non-specialists, yet almost 40% of PCPs are not comfortable making the diagnosis and 50% do not consider medical professionals prepared to care for people with AD, it is vital that PCPs receive education to help them stay abreast of these recent developments, be able to integrate them into practice where appropriate and in an evidence-based manner, and be aware of emerging developments in AD diagnosis and treatment.
The educational program, “A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment” will provide the latest AD clinical developments in a manner that is most relevant to the primary care setting and will provide access to AD resources and experts to help prepare them for the potential sea change in AD management.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
At the conclusion of this activity, participants should be able to:
- Integrate validated assessment tools and discuss available biomarker testing to diagnose Alzheimer’s disease early in the course of disease
- Make timely and appropriate referrals to AD specialists for patients with symptoms of AD or other dementias
- Assess the safety and efficacy profiles of current and emerging treatment options for Alzheimer’s disease
DATES AND TIMES
Thursday, February 24, 2022
6:30 – 7:30 PM ET (5:30 – 6:30 PM CT / 3:30 – 4:30 PM PT)
Hosted by the Michigan Academy of Family Physicians
Tuesday, April 19, 2022
6:30 – 7:30 PM PT (9:30 – 10:30 PM ET / 8:30 – 9:30 PM CT)
Hosted by the Nevada Academy of Family Physicians
Thursday, May 26th, 2022
7:00 – 8:00 PM CT (8:00 – 9:00 PM ET / 5:00 – 6:00 PM PT)
Hosted by the Louisiana Academy of Family Physicians
Sharon Cohen, MD, FRCPC
Neurologist and Medical Director
Toronto Memory Program
R. Scott Turner, MD, PhD
Professor of Neurology and Director, Memory Disorders Program
Georgetown University Medical Center
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABMS MOC APPROVAL STATEMENT
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory,A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment has met the requirements as a Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
- ABMS MOC Part II CME Activity
- Family Medicine
AAFP CREDIT DESIGNATION STATEMENT